Magnitude of Diabetes Comorbidity among People Living with HIV: A Systematic Review

Tilahun Nigatu Haregu1*, Brian Oldenburg1, Geoffrey Setswe2, Julian Elliott3

1Department of Epidemiology and Preventive Medicine, Monash University, Australia
2School of Health Sciences, Monash University, South Africa
3Infectious disease unit, Alfred Hospital, Melbourne, Australia

Abstract Although the clinical relationship between HIV/AIDS and Diabetes is well established, there is a little summarized evidence about the magnitude of Diabetes comorbidity among people living with HIV. The aim of this study was to summarize evidence on the incidence and prevalence of Diabetes comorbidity among people living with HIV. A systematic review of the incidence and prevalence of Diabetes comorbidity among people living with HIV was conducted. Studies reporting incidence and/or prevalence of diabetes among people living with HIV were retrieved from Embase and Medline databases. Selection of the studies was based on both relevance and quality. Study and outcome characteristics were extracted using a standardized checklist. Resulted were presented using narrative and graphic summaries. PRISMA checklist was used as a guide for reporting of the review results. A total of 12 studies met the inclusion and quality. In total of 43,296 people living with HIV, 1,144 incident cases of diabetes were identified over 174,574 person-years. The incidence rates of diabetes comorbidity as reported by these studies ranged from 5.72 to 23.8 per 1000 person-years. Similarly, a total of 1,724 prevalent cases of diabetes were identified among 41,068 people living with HIV. The reported prevalence rates ranged from 2.85% to 14.9%. High level of variability in the reported incidence and prevalence rates of diabetes comorbidity was observed. Generally, the findings are not in favour of a significantly increased magnitude of diabetes comorbidity in HIV.

Keywords HIV-Diabetes Comorbidity, Magnitude, Prevalence, Incidence

1. Introduction

While still having a disproportionate burden of infectious diseases, most low and middle income countries are now facing a rapidly emerging burden of Noncommunicable diseases. This epidemiological overlap is expected to result in higher rates of comorbidity[1]. It is generally well understood that infectious diseases increase the risk of non-communicable diseases. Conversely, non-communicable diseases also predispose people to infectious diseases[2]. Besides, some infectious diseases increase the risk of getting other infectious diseases resulting in higher coinfection rates[3]. This also holds true for Noncommunicable diseases. Hence, the interrelationships between diseases are so complex that comorbidities exist in a significant magnitude and are worth considering.

There is no standard definition of comorbidity. It may refer to diseases or disorders that exist together with an index disease; or it may refer to the co-occurrence of two or more diseases in an individual. Measurement of comorbidity is currently getting more attention in medical research. Data sources that are available to measure comorbidity include medical records, patient self-report, clinical judgement and administrative databases. Comorbidity can take four major forms in statistical analysis: a confounder, an effect modifier, an exposure and an outcome. Most comorbidity studies involve the development and application of comorbidity indices to understand the effect of comorbidities on defined health outcomes[4].

Diabetes comorbidity in HIV infection, the occurrence of Diabetes in an individual living with HIV, is receiving more concern in line with the emergence of diabetes as a major disease of public health importance in high HIV prevalent countries. Low and middle income countries which already have high magnitude of HIV are expected to share high burden of Diabetes comorbidity due to the increase in the incidence of Diabetes in these settings[5].

Though more is known about the clinical relationship between HIV and Diabetes and the factors associated with that relationship, little is known about the epidemiology of their comorbidity. With the emergence of double mortality burden in low and middle income countries, better understanding of the epidemiology of HIV-Diabetes comorbidity is essential[6, 7]. Data on the incidence and prevalence of Diabetes among people with HIV are available from different studies in different parts of the world. There are also several studies that have reported the effect of
antiretroviral treatment on the risk of developing Diabetes among people living with HIV. However, to the knowledge of the investigators, there is no research effort that summarizes altogether the incidence and prevalence of Diabetes comorbidity in HIV infection.

Therefore, the aim of this study was to review and summarize the incidence and prevalence of Diabetes comorbidity among people living with HIV and thereby to discuss their implications on possible integration of HIV and Diabetes programs.

2. Methods

2.1. Search Strategy and Study Selection

We searched studies reporting the incidence and/or prevalence of Diabetes comorbidity among people living with HIV from Embase and Medline electronic databases (March 2012). We used the key words of “HIV and Diabetes and incidence” and “HIV and Diabetes and prevalence” in Embase search. We used the MeSH terms “HIV infection” and “Diabetes mellitus” in Medline. The titles and abstracts of the identified studies were screened for eligibility. The references of the identified reviews were consulted without restriction to identify additional studies.

We reviewed the full texts of all the retrieved articles for assessment of eligibility. The inclusion of the articles in the review was based on the following eligibility criteria: 1) Studies reporting primary data (reviews were excluded); 2) studies reporting the prevalence and/or incidence of diabetes; 3) studies conducted entirely on people living with HIV; and 4) Studies reporting explicit study design, sample size, follow-up period, and outcome ascertainment.

For practical reasons, one author (TN) conducted the screening and the eligibility assessment and the other authors have re-checked the screening and the eligibility assessment process and outputs.

A total of 22 studies met the eligibility criteria. Nine of these have reported incidence of diabetes in people living with HIV. Sixteen studies have reported prevalence of diabetes comorbidity among people living with HIV. Three studies have reported both on the incidence and prevalence of diabetes comorbidity among people living with HIV.

2.2. Quality Assessment

Risk of bias in the incidence and prevalence estimates was assessed by using five major criteria (adequacy of sample size, patient selection methods used, diabetes diagnosis methods used, quality assurance schemes applied and analysis conducted to account for the effects of possible confounding factors). Each of these criteria were scored out of four points (4=Acceptable, 3=Adequate, 2=inadequate, 1=not acceptable) by two reviewers. Ten articles with scores less than half of the total score (<10 points) were excluded.

The main reason for exclusion was inadequate sample size used for the estimation of incidence and prevalence. The final 12 studies were included in this review.

2.3. Data Extraction

We have extracted two categories of data from the identified studies using pre-tested checklists. The first set of variables extracted were study characteristics including name of first author, year of publication, study design, follow-up period (if applicable), sample size, and study population characteristics (age, sex, Body Mass Index (BMI), treatment status). The second set of variables was outcome characteristics which include baseline prevalence (if applicable), incidence rates, prevalence rates and values for measures of association.

Two reviewers independently extracted data from the selected studies. Discrepancies were settled through consensus and by rechecking the individual study reports.

2.4. Synthesis Methods

For the included studies confidence intervals for the incidence and prevalence rates were recalculated using poison exact method in using Stata 12. As Meta-analysis of the incidence and prevalence rates was precluded by heterogeneity of the studies, we have summarized the findings of the review using narrative and graphic summaries.

3. Results

3.1. Study Characteristics

Of the 12 studies included in this systematic review, five have reported incidence and seven have reported on the prevalence (one study has reported both prevalence and incidence rates of diabetes). The search and selection of the studies is shown using the PRISMA flow diagram (Figure 1).

All the included studies have sample size of greater than 500 and were published between 2005 and 2012. Detailed study characteristics and outcome characteristics including the prevalence and incidence of diabetes (with 95% confidence interval) from the included studies are presented in Table 1.

3.2. Incidence of Diabetes Comorbidity

In the five incidence studies, a total of 43,296 people living with HIV were followed over a period of 174,574 person-years. During this follow-up period a total of 1,144 incident cases of diabetes were identified. The incidence rates of diabetes comorbidity as reported by these studies ranged from 5.72 to 23.8 per 1000 person-years. The review results of individual incidence studies are described as follows.
In the Data collection on adverse effects of anti-HIV drugs (D: A: D) study conducted in 33,389 people living with HIV who were receiving antiretroviral treatment, with average age of 38 years and average Body Mass Index (BMI) of 23.0 Kg/m², followed over 130,151 person-years of follow-up from 11 cohorts and 212 clinics in Europe, US, Argentina and Australia, diabetes was diagnosed in 744 patients. The incidence rate of diabetes in this study was 5.72 per 1,000
person-years of follow up. In this study, the incidence of Diabetes has increased with cumulative exposure to combination antiretroviral treatment. About three-fourths of the study subjects enrolled in to this study were men[8].

In the SwissHIV cohort study, 123 of 6,513 persons included in the follow up developed diabetes during 27,798 person-years of follow-up (mean duration of follow up was 4.3 years). This was equivalent to an incidence rate of 4.42 cases per 1000 person-years. This study has reported an increased incidence rate ratio among male study subjects and among those who use protease inhibitors and some nucleoside reverse transcriptase inhibitors (NRTI). The median age and the median BMI among the study subjects included in this cohort study were 38 years and 22.5 kg/m² respectively. Nearly 70% of the study subjects in this study were men[9].

In the Women’s Interagency HIV study conducted in six cities of United States, Diabetes was diagnosed in 116 HIV-infected (n=1524) and 36 HIV-uninfected (n=564) women over 6,802 person-years (4962 for HIV infected and 1840 for uninfected). The incidence of diabetes among HIV infected was about 2.33 cases per 100 person years. HIV-infected women who were not taking antiretroviral therapy had a diabetes incidence rate of 1.53 per 100 person years. Women who were taking highly active anti-retroviral treatment containing a protease inhibitor had a rate of 2.50 per 100 person-years and those reporting non-protease inhibitor-containing HAART had a rate of 2.89 per 100 person-years. The median age among the HIV positive women was 39.2 years while the median BMI was 26.8 kg/m². In this study, cumulative exposure to NRTI was associated with increased incidence of Diabetes[10].

In a cohort study of 1046 HIV-infected patients in 47 French clinical sites, representing 7,846 person-years of follow-up, 111 patients developed diabetes. The incidence rate was 14.1 per 1,000 person-years of follow up. The incidence rate in this study was 14.6 in men and 12.6 in women[11].

In another study conducted in Taiwan among 824 HIV-infected patients attended from 1993 to 2006 at National Taiwan University Hospital, 50 incident cases of Diabetes were diagnosed, resulting in an incidence of 13.1 cases per 1,000 person-years of follow-up. In this study, family history, exposure to zidovudine and current use of protease inhibitors were found to be the major risk factors for development of Diabetes[12]. The distribution of the incidence rates and their 95% confidence intervals are shown in the Figure 2.

### 3.3. Prevalence of Diabetes Comorbidity

In the seven studies that have reported prevalence of diabetes, 41,068 people living with HIV were studied. Among these population, 1,724 prevalent cases of diabetes were identified. The reported prevalence rates ranged from 2.85% in the D:A: D baseline prevalence to 14.9% in the baseline prevalence of veterans ageing cohort study.

In the Data Collection on Adverse Events of Anti-HIV Drugs Study, 952 of the 33,389 patients had diagnosis of diabetes at index visit. This makes the baseline prevalence of diabetes to be 2.85%[8]. In the veterans ageing cohort study of 3,227 HIV-infected individuals, the baseline prevalence of diabetes was 14.9% in the HIV infected as compared to 21.4% in the HIV uninfected group. Most of this difference was attributed to the differences in body mass index[13].

![Figure 2. Diabetes incidence rates (per 1000 person-years) and their 95% CI](image-url)
In a study of comparison of factors associated with prevalent diabetes mellitus among HIV-infected antiretroviral naive individuals enrolled in to Community Programs for Clinical Research on AIDS (CPCRA) clinical trials and adults enrolled in to the National Health and Nutritional Examination Survey (NHANES), the prevalence of self-reported Diabetes in the CPCRA clinical trials and the NHANES cohorts was 3.3% and 4.8%, respectively [14].

In a study of the prevalence of diabetes among 610 HIV positive asymptomatic patients in Botswana, the prevalence of diabetes was found to be 4.6% as compared to 7.2% for the general population in Botswana. Among those above 40 years of age, the prevalence was 10.8%. Older age and higher BMI were associated with higher diabetes prevalence in this study [15].

In a study conducted on 755 HIV positive individuals attending tertiary care hospital for routine clinical and laboratory follow-up between July and September 2009 in Italy, the prevalence of diabetes was found to be 4.5%. A longer exposure to antiretroviral therapy and a diagnosis of lipodystrophy syndrome were significantly associated with higher levels of diabetes prevalence [16].

In a study of 643 older men, the prevalence of diabetes based on Oral Glucose Tolerance Test and among HIV infected anti-retroviral naive individuals was 11% as compared to 8% in HIV uninfected individuals. In this study, age and Ethnicity were associated with abnormal Oral Glucose Tolerance Test (OGTT) results [17].

In the Multi-centre AIDS Cohort study, 68 (11.97%) of the 568 HIV-infected men had prevalent Diabetes at the baseline visit. The prevalence of diabetes was 14% among those 411 HIV positive men who were using antiretroviral treatment. Among 157 HIV positive men who were not using highly active anti-retroviral treatment, 11 have diabetes and the prevalence of Diabetes at index visit among this group was about 7% [18].

4. Discussion

The incidence of Diabetes comorbidity among people living with HIV generally looks to be similar to that of the general population. But this incidence has shown higher variability between studies with higher person years of follow up and those studies with relatively lower person years of follow up. Studies with higher person years of follow up seem to have a lower incidence of diabetes comorbidity than those with lower person years of follow up. The D: A : D study and the Swiss cohort study [8, 9] which have very high person years of follow up have reported incidence rates which are lower than all other reported values.

The prevalences of Diabetes comorbidity, which were outputs of cross-sectional studies in most cases, have also shown wider variability among the included studies. The prevalence of Diabetes in the respective general population, the socio-demographic profiles of the study subjects and duration on treatment may be the main factors related with this variability.

The relatively higher level of incidence and prevalence of diabetes among people living with HIV, and particularly among those who are receiving anti-retroviral treatment, warrants the screening of PLHIV for hyperglycaemia both at time of enrolment and during follow up period of HIV treatment. Whether this screening should be universally implemented for all people living with HIV or selectively for those with other risk factors needs further investigation. Screening during follow up periods while a person is on HIV treatment should also be the main stay in the prevention and control of diabetes among people living with HIV. Thus,
diabetes screening programs need to be integrated with HIV treatment programs.

With regard to the limitations of this study, aggregation of the incidence and prevalence of diabetes comorbidity among people living with HIV in to a single summary figure was not possible due to the heterogeneity of the included studies. This heterogeneity has also increased the variability among the reported incidence and prevalence rates. Another limitation of this study is that it was not possible to present the disaggregated incidence and prevalence rates for PLHIV taking ART and those not taking ART as only a few of studies have reported disaggregated values. Lastly, diabetes incidence and prevalence rates for the general population from which the study subjects were drawn were not available for comparison.

In conclusion, this review has summarized the incidence and prevalence of diabetes comorbidity among people living with HIV. High variability in the reported incidence and prevalence rates were observed among the studies. Comparison of diabetes incidence and prevalence between HIV infected and uninfected people is also not consistent among studies. Diabetes prevalence in the general population, sample sizes, duration of follow up and year of the study may be the possible factors associated with this variability. The study findings, in general, are not in favour of a significantly increased magnitude of diabetes comorbidity among people living with HIV. However, given the lower average age of the study participants, regular monitoring and screening of blood sugar levels of people living with HIV are recommended.

Funding: None

Conflict of interest: None declared

Ethical approval: Not required

REFERENCES


